Teva Pharmaceutical Industries Ltd. announces the approval of the generic equivalent to Lovaza® (omega-3-acid ethyl esters aapsules, USP), in the United States. “Teva believes it is first-to-file and thus far is the only company to receive an approval from FDA,” said the company. Teva plans to commence shipping immediately.

Lovaza® Capsules, marketed by GlaxoSmithKline, had annual sales of approximately $1.1 billion in the United States, according to IMS data as of December 2013, cited Teva in its press statement.

Source: Teva Pharmaceutical Industries